EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY 4.0

Effect of Iberogast (STW5) on tolerance to colonic gas in patients with irritable bowel syndrome: A randomized, double‐blind, placebo control clinical trial

Ariadna Aguilar, Bouchra Benslaiman, Jordi Serra iD

Neurogastroenterology & Motility · 2024

DOI: 10.1111/nmo.14765 ↗

At a glance

Randomisierte kontrollierte Studie in Neurogastroenterology & Motility, 2024. Written by Ariadna Aguilar and 2 co-authors. Institution: Digestive System Research Unit, University Hospital Vall d'Hebrón, Barcelona, Spain. Major MEDLINE topics: Irritable Bowel Syndrome, Cross-Over Studies. Cited 9 times so far (Crossref); 46 references. The full text is freely available (open access, CC BY 4.0). Funded by: Bayer Fund.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

STW5 is an herbal medicinal product that, in previous studies, reduced abdominal pain in irritable bowel syndrome (IBS). The effect of STW5 on gas‐related abdominal symptoms is unknown.

Aim

To determine the effects of STW5, compared to placebo, on the responses to colonic gas in IBS.

Methods

Using a cross‐over design, two gas challenge tests were performed in 10 patients with IBS and bloating after 2‐weeks treatment with (a) STW5 and (b) placebo. The challenge test consisted in continuous infusion of gas into the colon (24 mL/min for 60 min), followed by a 30‐min free evacuation period. Gas evacuation, symptom perception, and abdominal distension were continuously registered.

Results

Colonic gas filling was associated to a significant rise in abdominal symptom perception, that was significantly greater when patients were on‐placebo (score increment 4.0 ± 0.3) compared with on‐STW5 (score increment 3.2 ± 0.4; p = 0.035). Gas filling was associated to a progressive abdominal distension that was similar with both treatments. Opening of the rectal cannula produced a massive gas evacuation, similar after both treatments, associated to a return of abdominal perception and distension to basal levels when patients were on‐STW5 (score increment −0.1 ± 0.4; distension 0.3 ± 0.2 cm; p = 0.399, and p = 0.112 vs. basal), whereas both remained increased on‐placebo (score increment 0.5 ± 0.3; distension 0.8 ± 0.3 cm; p = 0.048, and p = 0.016 vs. infusion start).

Conclusions

STW5 improves colonic gas tolerance in IBS patients with bloating without a significant effect on gas retention and evacuation. This medicinal product can be beneficious for treatment of gas‐related abdominal symptoms in patients with bloating. EudraCT: 2019‐003976‐38.

Subjects

MeSH terms (MEDLINE)

Irritable Bowel SyndromeCross-Over StudiesHumansDouble-Blind MethodFemaleAdultMaleMiddle AgedPlant ExtractsColonGasesTreatment OutcomeAbdominal PainYoung AdultFlatulence

Author keywords

STW‐5abdominal distensionbloatingcolonic gasirritable bowel syndrome

Substances

iberogastPlant ExtractsGases

Authors and institutions

  • Digestive System Research Unit, University Hospital Vall d'Hebrón, Barcelona, Spain.
  • Autonomous University of Barcelona, Barcelona, Spain.
  • Motility and Functional Gut disorders Unit, University Hospital Germans Trias i Pujol, Badalona, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.

ORCID profiles: Jordi Serra

Funding

  • Bayer Fund

Cite

APA

Aguilar, A., Benslaiman, B., & Serra, J. (2024). Effect of Iberogast (STW5) on tolerance to colonic gas in patients with irritable bowel syndrome: A randomized, double‐blind, placebo control clinical trial. Neurogastroenterology & Motility. https://doi.org/10.1111/nmo.14765

Vancouver

Aguilar A, Benslaiman B, Serra J. Effect of Iberogast (STW5) on tolerance to colonic gas in patients with irritable bowel syndrome: A randomized, double‐blind, placebo control clinical trial. Neurogastroenterology & Motility. 2024. doi:10.1111/nmo.14765

BibTeX
@article{Aguilar2024,
  author = {Aguilar, Ariadna and Benslaiman, Bouchra and Serra, Jordi},
  title = {Effect of Iberogast (STW5) on tolerance to colonic gas in patients with irritable bowel syndrome: A randomized, double‐blind, placebo control clinical trial},
  journal = {Neurogastroenterology & Motility},
  year = {2024},
  doi = {10.1111/nmo.14765}
}
Start for free →